GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling

• Published in: Cancer gene therapy 2021-08, Vol.28 (7-8), p.839-849
• Main Authors: Huang, Longping, Chen, Si, Fan, Haijun, Ji, Dawei, Chen, Chuanping, Sheng, Weiwei
• Format: Article
• Language: English
• Subjects: 13; 13/109; 13/95; 38/1; 38/89; 42; 631/67/2332; 631/80; 82/80; 96; 96/95; Aged; Animals; Biomedical and Life Sciences; Biomedicine; Cancer; Cell differentiation; Cellular signal transduction; Chromosomal Proteins, Non-Histone - metabolism; Cytology; Development and progression; Disease Models, Animal; E-cadherin; Epithelial cells; Epithelial-Mesenchymal Transition; Extracellular signal-regulated kinase; Female; Gene Expression; Gene Therapy; Genetic aspects; Health aspects; Humans; MAP kinase; MAP Kinase Signaling System - genetics; Medical prognosis; MEK inhibitors; Mesenchyme; Metastases; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases - genetics; Oncogenes; Oncology, Experimental; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - genetics; Patients; Prospective Studies; Protein kinases; Signal transduction; Stem cells; Vimentin
• ISSN: 0929-1903; 1476-5500
• DOI: 10.1038/s41417-020-0206-7

Go-Ichi-Ni-San 2 (GINS2), as a newly discovered oncogene, is overexpressed in several cancers. However, the specific role of GINS2 in the development of pancreatic cancer (PC), to our knowledge, is poorly understood. We systematically explored the potential role of GINS2 in epithelial–mesenchymal-transition (EMT)-stimulated PC in vitro and vivo. GINS2 was overexpressed in human PC specimens, which was positively associated with tumor size ( P  = 0.010), T stage ( P  = 0.006), vascular invasion ( P  = 0.037), and the poor prognosis ( P  = 0.004). Interestingly, a close correlation between GINS2, E-cadherin, and Vimentin ( P  = 0.014) was found in human PC specimens and cell lines that coordinately promoted the worse survival of PC patients ( P  = 0.009). GINS2 overexpression stimulated EMT in vitro, including promoting EMT-like cellular morphology, enhancing cell motility, and activating EMT and ERK/MAPK signal pathways. However, PD98059, a specific MEK1 inhibitor, reversed GINS2 overexpression-stimulated EMT in vitro. Conversely, GINS2 silencing inhibited EMT in PANC-1 cells, which was also rescued by GINS2-GFP. Moreover, GINS2 was colocalized and co-immunoprecipitated with ERK in GINS2 high-expression Miapaca-2 and PANC-1 cells, implying a tight interaction of GINS2 with ERK/MAPK signaling. Meanwhile, GINS2 overexpression inhibited distant liver metastases in vivo, following a tight association with EMT and ERK/MAPK signaling, which was reversed by MEK inhibitor. Overexpression of GINS2 contributes to advanced clinical stage of PC patient and promotes EMT in vitro and vivo via specifically activating ERK/MAPK signal pathway.